Cyclerion Therapeutics, Inc. CYCN
We focus on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical need. Our current strategic focus is centered on the development of a novel therapeutic approach for neuropsychiatric conditions, with the lead indication being treatment-resistant depression ("TRD"), which we believe represents a substantial clinical and commercial opportunity.
Primary Focus on New Potential Treatment for Treatment Resistant Depression ("TRD")
Over the past year, we have refined our strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and prioritized CYC-126, an individualized therapy for TRD as our foundational development program.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297.0K | $3.9M | $2.3M | $4.5M | — | — |
| R&D | $959.0K | $286.0K | $1.5M | $6.0M | $37.6M | $56.4M | $95.1M | $87.7M | — |
| SG&A | $6.1M | $5.3M | $8.1M | $12.9M | $20.6M | $28.8M | $34.4M | $27.5M | — |
| Total operating expenses | $7.0M | $5.6M | $2.4M | $18.8M | $59.1M | $83.6M | $129.5M | $115.3M | — |
| Operating income | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M | -$81.3M | -$125.0M | -$115.3M | — |
| Pre-tax income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M | -$122.4M | -$122.4M | -$115.3M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M | -$77.8M | -$123.0M | -$115.3M | — |
| EPS, basic | -1.11 | -1.21 | -2.25 | -20.28 | -1.32 | — | — | — | — |
| EPS, diluted | -1.11 | -1.21 | -2.25 | -20.28 | -1.32 | -2.56 | -4.49 | -4.21 | — |
| Shares, diluted (wtd. avg.) | $3.2M | $2.5M | $2.3M | $2.2M | $39.1M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M | $58.2M | $102.6M | $0 | $0 |
| Receivables | $1.0M | $556.0K | $0 | $96.0K | $100.0K | $0 | — | — | — |
| Total current assets | $4.6M | $4.2M | $8.0M | $14.8M | $55.5M | $58.5M | $101.2M | $879.0K | — |
| Property, plant and equipment | — | $0 | $0 | $0 | $65.0K | $6.9M | $11.6M | $6.5M | — |
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M | $115.4M | $186.5M | $7.4M | — |
| Accounts payable | $508.0K | $390.0K | $1.2M | $3.0M | $1.8M | $1.1M | $3.2M | $2.8M | — |
| Short-term debt | — | — | — | $3.5M | $3.5M | $3.5M | — | — | — |
| Total current liabilities | $900.0K | $725.0K | $2.1M | $7.6M | $11.1M | $17.0M | $18.2M | $17.8M | — |
| Retained earnings | -$271.0M | -$267.5M | -$264.4M | -$259.2M | -$215.1M | -$163.4M | -$85.6M | — | — |
| Total equity | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M | $59.5M | $97.7M | -$10.4M | -$8.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M | -$72.5M | -$102.2M | -$97.5M | — |
| Stock-based compensation | $441.0K | $625.0K | $1.1M | $6.3M | $9.6M | $15.0M | $19.6M | $12.4M | — |
| Capital expenditure | — | — | — | $0 | $7.0K | $1.5M | $6.9M | $3.4M | — |
| Investing cash flow | — | $0 | $10.4M | $0 | $1.5M | $18.0K | -$6.7M | -$3.4M | — |
| Financing cash flow | $3.3M | $0 | $5.0M | $29.0K | $30.8M | $28.1M | $211.6M | $100.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-312558.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |